DENVER, Colo., Oct 16, 2024 (247marketnews.com)- Biodexa Pharmaceuticals (NASDAQ: BDRX) stated that its request for an extension of time to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq Stock Market LLC was approved by a Nasdaq Hearings Panel.
To move forward, Biodexa Pharmaceuticals must remain in compliance with Nasdaq Listing Rule 5550(a)(2), or the “Minimum Bid Price Requirement”. The Panel’s decision is contingent on the Company maintaining a closing bid price of at least $1.00 per share for at least 20 consecutive trading days by October 31, 2024.
The post 24/7 Market News- Biodexa Successfully Appeals Nasdaq Delisting appeared first on 24/7 MarketNews.
